|1.||Liver Diseases (Liver Disease)
|2.||Acute Liver Failure (Fulminant Hepatic Failure)
|1.||Huo, Teh-Ia: 26 articles (03/2015 - 12/2004)|
|2.||Lin, Han-Chieh: 24 articles (03/2015 - 12/2004)|
|3.||Busuttil, Ronald W: 22 articles (11/2015 - 09/2002)|
|4.||Lee, Shou-Dong: 22 articles (07/2010 - 12/2004)|
|5.||Kim, W Ray: 20 articles (05/2015 - 04/2003)|
|6.||Kamath, Patrick S: 18 articles (07/2015 - 04/2003)|
|7.||Lee, Pui-Ching: 18 articles (03/2010 - 12/2004)|
|8.||Rossi, M: 16 articles (09/2013 - 04/2004)|
|9.||Samuel, Didier: 15 articles (09/2015 - 03/2005)|
|10.||Merion, Robert M: 15 articles (09/2015 - 10/2004)|
10/07/2013 - "An increase in albumin (F = 18.9 and 17.3), decrease in total bilirubin and in ALT (F = 16.5, 17.1 and 23.7, 24.8), reduced PT (F = 22.7 and 24.5), and improved Child-Turcotte-Pugh and the model for end-stage liver disease scores (F = 18.5, 17.8, and 24.2, 23.8) were observed in both groups. "
05/01/2008 - "In the present study, we report a confirmed case of a girl of 1 year of age with increased bilirubin of 28.5 mg/dL and pediatric end-stage liver disease score 20. "
08/01/2015 - "GSTP1 methylation level was significantly correlated with total bilirubin (r = 0.29, P < 0.01), prothrombin time activity (r = -0.24, P = 0.01) and model for end-stage liver disease (MELD) score (r = 0.26, P = 0.01). "
05/01/2015 - "Furthermore, in cirrhotics, sCD146 correlated positively with AST, bilirubin levels and most importantly with international normalized ratio and model for end-stage liver disease (r = 0.648, p < 0.001 and r = 0.567, p < 0.001, respectively). "
01/01/2015 - "Alcohol consumption, use of antituberculosis drugs, serum total bilirubin, direct bilirubin, total protein, albumin, thrombinogen time, international normalized ratio, and the model for end-stage liver disease (MELD) score were significantly correlated with DILI-associated mortality. "
|2.||Cytidine Triphosphate (CTP)IBA
06/01/2011 - "Recent studies have suggested that the model for end-stage liver disease (MELD) score is superior to the Child-Turcotte-Pugh (CTP) score as a predictor of postoperative mortality, especially up to 90 days. "
09/01/2013 - "APACHE II score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF)."
02/01/2010 - "ETV treatment for 12 months resulted in improved Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores. "
11/01/2014 - "Previous studies have reported conflicting results about the value of Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores as predictors of post-operative mortality. "
08/01/2012 - "This study evaluated the results of cardiac surgery in cirrhotic patients and the relevance of EuroSCORE, Child-Turcotte-Pugh (CTP) class and model for end-stage liver disease (MELD) score in terms of prediction of surgical mortality and survival. "
05/01/2010 - "The model for end-stage liver disease - sodium (MELDNa) incorporates serum sodium and has been shown to improve the predictive accuracy of the MELD score. "
12/01/2015 - "This study sought to assess performance of preoperative Model for End-Stage Liver Disease (MELD) score in predicting postoperative mortality in LDLT and to compare it with other scores: MELDNa, United Kingdom End-Stage Liver Disease (UKELD), MELD to serum sodium ratio (MESO), updated MELD, donor age-MELD (D-MELD) and integrated MELD (iMELD). "
10/01/2009 - "Published data suggest that integrating serum sodium and model for end-stage liver disease may improve the score prognostic accuracy but further studies are necessary to confirm this issue. "
12/01/2015 - "Potential predictors with a p value <0.1 were further analyzed after adjustment for covariates (Model for End-stage Liver Disease score, serum sodium, number of medications). "
11/01/2015 - "The IPVD group had a trend toward higher Model for End-Stage Liver Disease score with and without incorporating sodium (MELD or MELD-Na; P = 0.05 for both). "
|4.||Lamivudine (3TC)FDA Link
11/01/2014 - "Prediction of prognosis to lamivudine in patients with spontaneous reactivation of hepatitis B virus-related acute-on-chronic liver failure: using virologic response at week 4."
06/01/2012 - "To observe the therapeutic effects of lamivudine treatment in patients with early- to mid-stage hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). "
10/27/2002 - "Lamivudine has an important role in patients with end-stage liver disease caused by HBV precore mutant strain. "
12/01/2007 - "Forty-two patients started salvage therapy a median of 5 months after lamivudine failure; the median Model for End-Stage Liver Disease (MELD) score was 12. "
07/01/2000 - "Lamivudine, an oral nucleoside analogue, is a potent inhibitor of HBV replication and has been investigated in end-stage liver disease and liver transplantation. "
06/21/2015 - "This improvement in albumin was, however, not sustained at 3 mo. However, at the end of 3 mo there was a statistically significant improvement in serum creatinine in the study group (0.96 ± 0.33 vs 1.42 ± 0.70, P = 0.01) which translated into a significant improvement in the Model for End-Stage Liver Disease score (15.75 ± 5.13 vs 19.94 ± 6.68, P = 0.04). "
01/01/2013 - "In 84 OLT recipients (42 RS, 42 SLK) Model for End-Stage Liver Disease and creatinine were similar at OLT, with improved creatinine at 1 year (all P < .01 from OLT). "
07/01/2015 - "Therefore, the aim of this study was to determine prognostic factors for SBP-related in-hospital mortality, and to evaluate the predictive power of Child-Pugh (CP), model of end-stage liver disease (MELD), creatinine modified Child-Turcotte-Pugh (CrCTP), and integrated MELD (iMELD) for identifying the best score to predict mortality. "
03/01/2012 - "This study aimed to evaluate the impact of two creatinine measurement methods on the Model for End Stage Liver Disease (MELD) score and glomerular filtration rate estimation (eGFR) in cirrhotic patients. "
10/01/2010 - "The aim of this study was to reassess correlations between creatinine-based equations and measured glomerular filtration rate (GFR) and to investigate the impact of inaccuracies on the Model for End-Stage Liver Disease (MELD) score. "
|6.||Granulocyte Colony-Stimulating Factor (G-CSF)IBA
02/21/2013 - "To evaluate the safety and efficacy of granulocyte-colony stimulating factor (G-CSF) therapy in patients with hepatitis B virus (HBV)-associated acute-on-chronic liver failure (ACLF). "
01/01/2013 - "To explore the efficacy of G-CSF mobilization in the treatment of chronic liver failure (CLF) and the mechanism of its action. "
09/01/2015 - "The aim of this study was to assess the benefits and harms of G-CSF in patients with acute-on-chronic liver failure. "
12/01/2015 - "Autologous CD133(+) stem/progenitor cells, mobilized with granulocyte-colony stimulating factor, were collected by leukapheresis and reinfused at increasing doses through the hepatic artery starting from 5×10(4)/kg up to 1×10(6)/kg. 16 subjects with Model for End-stage Liver Disease (MELD) score between 17 and 25 were enrolled, 14 mobilized an adequate number of CD133(+) stem/progenitor cells and 12 were reinfused. "
09/01/2015 - "Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis."
|7.||Hepatitis B e AntigensIBA
02/01/2013 - "Chronic hepatitis B (CHB) in serum HBeAg negative patients is a difficult to cure, progressive disease leading to end-stage liver disease and hepatocellular carcinoma. "
06/01/2010 - "HBeAg-positive rates of genotype C in acute-on-chronic liver failure group, cirrhosis group, hepatocellular carcinoma group were higher than that of genotype B (P = 0.000, 0.024, 0.003). "
12/01/2011 - "We also evaluated the clinical significance of age, gender, location of portal vein tumor thrombus, HBeAg, tumor histological grade, Child-Pugh classification, end-stage liver disease (MELD) score, advanced liver cancer prediction system (ALCPS) score and the Eastern Cooperative Oncology Group performance status (ECOG PS) score for predicting the efficacy of cryoablation. "
10/01/2011 - "Evaluate clinical significance of age, gender, location of portal vein tumor thrombus, HBeAg, tumor histological grade, Child-Pugh classification, end-stage liver disease (MELD) score, advanced liver cancer prediction system (ALCPS) score and the Eastern Cooperative Oncology Group performance status (ECOG PS) score for predicting the efficacy of cryoablation. "
08/01/2013 - "A novel acute-on-chronic liver failure scoring system can syllabify differentiate the relations between the opportunities and efficacies on the Entecavir treatment for HBeAg-negative ACLF."
01/01/2012 - "Moreover, entecavir was associated with significantly greater reduction of the model for end-stage liver disease scores (median 10.0 versus 4.3; P=0.02). "
06/01/2013 - "Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B."
10/01/2012 - "Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model."
09/01/2011 - "Entecavir treatment for 12 months decreased mean Model for End-Stage Liver Disease scores in patients with cirrhosis and HCC (7.2 vs 5.6, P < 0.001). "
11/01/2013 - "Among patients with liver cirrhosis (482 entecavir-treated, 69 treatment-naïve), entecavir-treated patients had reduced risks of all clinical outcomes when compared with treatment-naïve patients with cirrhosis after adjusted for model for end-stage liver disease score: hepatic events (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.34-0.78; P = 0.002), HCC (HR, 0.55; 95% CI, 0.31-0.99; P = 0.049), liver-related mortality (HR, 0.26; 95% CI, 0.13-0.55; P < 0.001), and all-cause mortality (HR, 0.34; 95% CI, 0.18-0.62; P < 0.001). "
10/01/2005 - "The aim of this study was to evaluate the ability of a minimally invasive, highly sensitive optical sensing device to detect ammonia in the breath of patients with end-stage liver disease and to evaluate the correlation of breath ammonia levels, arterial ammonia levels, and psychometric testing. "
01/01/2005 - "The results of this study demonstrate a significant relationship between TNF and ammonia in patients with chronic liver failure and HE, and so strengthen the suggestion that TNF could be strongly involved in the pathogenesis of HE in these patients. "
12/01/2002 - "Positron emission tomography studies using 13HN3 provide evidence of increased blood-brain ammonia transfer and brain ammonia utilization rates in patients with chronic liver failure. "
12/01/2002 - "Results of neuropathologic, spectroscopic, and neurochemical studies continue to confirm a major role for ammonia in the pathogenesis of the central nervous system complications of both acute and chronic liver failure. "
03/01/2015 - "Death from neurological sequelae was considered imminent for these patients, and this was further reflected in significantly higher international normalized ratios and ammonia levels and worse prognostic liver indices (Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease scores and liver injury units) in comparison with 32 wait-listed patients who did not receive MARS dialysis. "
02/01/2009 - "This study attempts to determine expressions of intrahepatic proinflammatory and anti-inflammatory cytokines and their secreting immunocytes to evaluate their roles in the pathogenesis of acute-on-chronic liver failure (ACLF) in chronically hepatitis B virus (HBV)-infected patients. "
02/01/2013 - "CD34+ hematopoietic stem cells mobilization, paralleled with multiple cytokines elevated in patients with HBV-related acute-on-chronic liver failure."
01/01/2011 - "To this end, we analyzed the expression patterns of Foxp3- and IL-23/IL-17 pathway-related proinflammatory cytokines in 39 patients with acute-on-chronic liver failure, 71 patients with CHB and 32 healthy controls. "
01/01/2009 - "Role of cytokines in the pathophysiology of acute-on-chronic liver failure."
01/01/2007 - "Albumin dialysis systems do not appear to significantly decrease serum concentrations of inflammatory cytokines in severe acute on chronic liver failure. "
06/02/2013 - "The most effective treatment of end-stage liver disease is liver transplantation. "
12/01/2011 - "Orthotopic liver transplantation (OLT) is the most effective treatment for patients with end-stage liver disease to date. "
10/01/2011 - "Liver transplantation is a highly effective treatment for end-stage liver disease. "
07/14/2011 - "Liver transplantation is considered as the most effective treatment for end-stage liver disease. "
10/01/2010 - "Liver transplantation (LT) is the best treatment option for patients with end-stage liver disease. "
04/01/2015 - "Liver transplant currently is the best treatment option for end-stage liver disease. "
07/01/2010 - "Group 1 had both higher Model for End-Stage Liver Disease score and Child-Pugh score than Group 2. Portal venous flow volume just after reperfusion was significantly greater in Group 1 than Group 2 (307.8±268.8 vs. 176.2±75.0 mL/min/100 g graft weight, respectively; p<0.05). "
05/01/2009 - "Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft."
01/01/2013 - "The MELD score is superior to other prognostic models in patients with end-stage liver disease, such as the Child-Turcotte-Pugh score, since it uses only objective criteria, and its implementation in 2002 led to a sharp reduction in the number of people waiting for liver transplant and reduced mortality on the waiting list without affecting posttransplant survival. "
12/01/2015 - "Implementation of EPCI improved symptom burden and mood in end-stage liver disease patients awaiting transplant."
|3.||Transplantation (Transplant Recipients)
04/01/2013 - "Patients with HBV-related end-stage liver disease displayed significantly improved liver function after PBSCs transplantation. "
03/01/2014 - "To investigate the efficacy of hematopoietic stem cell (HSC) transplantation via the hepatic artery vs. the portal vein for end-stage liver disease (ESLD). "
01/01/2013 - "Liver function and MELD (model for end-stage liver disease) scores improved and he currently does not require listing for transplantation. "
09/01/2006 - "Survival rates in transplant recipients have improved as a result of advances in immunosuppression and proper risk stratification using the Model for End-Stage Liver Disease and Child-Turcotte-Pugh scoring systems."
08/27/2001 - "Our data suggest that if nutritional repletion is possible in patients with end-stage liver disease before transplantation, patient outcomes could be improved."
10/01/1990 - "Organ transplantation offers increased survival and improved quality of life to many patients with end-stage liver disease. "
05/01/2014 - "In this study we enrolled 75 patients with end-stage liver disease who underwent OLT from February 2010 until September 2010 at the Shiraz Organ Transplantation Center. "
01/01/2010 - "The only presently viable treatment for end-stage liver disease is whole organ transplantation. "
08/01/2009 - "The clinical demand for whole organ transplantation for the treatment of end-stage liver disease far outstrips supply. "
08/01/2004 - "Independent variables were age, gender, race, pediatric end-stage liver disease score (PELD), year of transplantation, organ type, primary disease, length of operation, and insurance status. "
11/01/2004 - "Combined liver-kidney transplantation is safe (low morbidity and acceptable mortality) and effective in patients with end-stage liver disease. "
09/01/2015 - "After introduction of the Model for End-Stage Liver Disease (MELD) score in 2002, a worldwide increasing number of simultaneous liver-kidney transplantations (SLKTx) has been observed. "
07/01/2013 - "Experience of combined liver-kidney transplantation for acute-on-chronic liver failure patients with renal dysfunction."
08/01/2012 - "Since the adoption of the Model for End-Stage Liver Disease, the number of simultaneous liver-kidney transplantation (SLK) procedures has increased. "
09/01/2011 - "Since implementation of the Model for End-stage Liver Disease (MELD), the number of simultaneous liver-kidney transplantations (SLKT) has increased in the United States. "